Author

Geert R. D'Haens

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens  et al.

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Geert R. D'Haens  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Geert R. D'Haens  et al.

EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL
EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF VIDOFLUDIMUS CALCIUM (IMU-838) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PROSPECTIVE PLACEBO-CONTROLLED PHASE 2 CALDOSE-1 TRIAL
EFFICACY AND SAFETY OF VIDOFLUDIMUS CALCIUM (IMU-838) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PROSPECTIVE PLACEBO-CONTROLLED PHASE 2 CALDOSE-1 TRIAL

Geert R. D'Haens  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY
COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert R. D'Haens  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Geert R. D'Haens  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Geert R. D'Haens  et al.

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH
PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

Geert R. D'Haens  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Geert R. D'Haens  et al.

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Geert R. D'Haens  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens  et al.

EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Geert R. D'Haens  et al.

Item 21 - 40 / 98
1
2
3 4 5